Servier, Prognomix Agree to ID Targets for Diabetes, Metabolic Disease Treatments | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Les Laboratoires Servier and Prognomix today announced a deal to identify novel targets for the development of type 2 diabetes and metabolic disease treatments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.